HC Wainwright Predicts Cibus’ FY2029 Earnings (NASDAQ:CBUS)

Cibus, Inc. (NASDAQ:CBUS) – Investment analysts at HC Wainwright increased their FY2029 earnings estimates for shares of Cibus in a research report issued on Friday, March 27th. HC Wainwright analyst A. Dayal now anticipates that the company will post earnings of $0.31 per share for the year, up from their prior forecast of $0.27. The consensus estimate for Cibus’ current full-year earnings is ($2.96) per share. HC Wainwright also issued estimates for Cibus’ FY2030 earnings at $2.12 EPS.

CBUS has been the topic of several other reports. Canaccord Genuity Group restated a “buy” rating and set a $15.00 price objective on shares of Cibus in a report on Monday, December 8th. Jefferies Financial Group increased their target price on Cibus from $1.90 to $3.00 and gave the company a “hold” rating in a research note on Wednesday, March 25th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Cibus in a research report on Wednesday, January 21st. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $9.00.

Cibus Trading Up 8.8%

NASDAQ:CBUS opened at $1.98 on Monday. The stock has a market cap of $137.02 million, a price-to-earnings ratio of -0.66 and a beta of 1.62. Cibus has a one year low of $1.09 and a one year high of $4.19. The company has a debt-to-equity ratio of 1.37, a quick ratio of 0.72 and a current ratio of 0.72. The business’s 50-day simple moving average is $2.71 and its 200 day simple moving average is $1.96.

Cibus (NASDAQ:CBUS) last announced its earnings results on Tuesday, March 17th. The company reported ($0.42) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.01. Cibus had a negative return on equity of 174.58% and a negative net margin of 3,492.30%.The company had revenue of $1.06 million during the quarter, compared to the consensus estimate of $1.64 million.

Institutional Trading of Cibus

Hedge funds and other institutional investors have recently bought and sold shares of the company. Gratia Capital LLC bought a new position in Cibus during the 2nd quarter worth approximately $1,183,000. Transce3nd LLC increased its holdings in shares of Cibus by 29.1% in the 2nd quarter. Transce3nd LLC now owns 52,656 shares of the company’s stock valued at $75,000 after acquiring an additional 11,861 shares during the last quarter. BDT Capital Partners LLC increased its holdings in shares of Cibus by 1,899.7% in the 4th quarter. BDT Capital Partners LLC now owns 63,410 shares of the company’s stock valued at $110,000 after acquiring an additional 60,239 shares during the last quarter. Goldman Sachs Group Inc. raised its position in shares of Cibus by 60.4% during the 4th quarter. Goldman Sachs Group Inc. now owns 52,364 shares of the company’s stock valued at $91,000 after acquiring an additional 19,717 shares in the last quarter. Finally, Squarepoint Ops LLC bought a new position in Cibus during the third quarter worth $62,000. 33.81% of the stock is owned by institutional investors.

Cibus Company Profile

Cibus, Inc is a biotechnology company specializing in precision gene editing for agricultural applications. Leveraging its proprietary Rapid Trait Development System (RTDS), Cibus develops improved crop traits without the introduction of foreign DNA. The company’s platform enables targeted modifications to plant genomes, allowing for enhanced disease resistance, herbicide tolerance and yield optimization in key row crops.

The company’s core business centers on trait development services and licensing partnerships.